Clinical trials: Treatment Failure

Advanced NSCLC

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

• Completed
• Age: 18 to 86 years
• Phase 4
• Results posted

Although some small sample studies have reported the possible resistance mechanisms of Osimertinib in the first-line treatment, it is still an urgent need to explore the whole gene profile in EGFRm advanced NSCLC patients post…

Trial name

GPS (NCT05219162)

Testing

Gene Profile explore

Where

16 sites in China

Volunteers

182 people

Sponsor

AstraZeneca